Looking for factors that predict outcomes in pituitary tumors after surgery
Collects patient data to build a prognosis classification for pituitary tumors after surgery.
Key facts
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Twenty-years' Experience in Pituitary Disease.
- Status
- Recruiting
- People taking part
- 1,600 people, planned
- Started
- 10 Mar 2025
- Expected to end
- 30 Apr 2028
- Type of study
- Observational
- Treatments tested
- Frequency of disease recurrence
- Record updated
- 15 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had surgery to remove a pituitary tumor. Their data will be studied to find signs that predict how the disease goes.
- Age
- Older than 18 years at diagnosis of the pituitary tumor.
- Sex
- All sexes can join.
- Disease stage
- A pituitary tumor confirmed by a lab exam of the tissue (pathology diagnosis).
- Earlier treatment
- People must have had surgery for the pituitary tumor.
Main reasons for not taking part
- Age lower than 18 years
- Follow-up shorter than 2 years
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients underwent surgery for pituitary tumors
- pathology diagnosis of pituitary tumors
- patients older then 18 years at diagnosis of pituitary tumors
- 2 years follow-up
Who cannot take part
- age lower then 18 years
- follow-up shorter than 2 years
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.
The group in the trial
- Patients with pituitary tumors
Patients with pituitary tumors, underwent surgical resection
Treatment: Frequency of disease recurrence
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors
- Plain-language title
- Looking for factors that predict outcomes in pituitary tumors after surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 15 May 2025